NSCLC靶向及免疫治疗,1,000 例肺腺癌标本驱动基因突变状态: 来自 NCI 肺癌突变联盟(LCMC)的报道,单个驱动基因突变状态的发生率,Kris MG. et al. ASCO 2011, Abstract # 7506.,Molecular events in lung adenocacinoma,Chinese,Caucasians,中国人与白种人驱动基因比较,肺癌中主要的突变情况,Current Clinically Relevant Pathways,EGFR mutation: Erlotinib ,Gefitinib,Afatinib,Osimertinib KRas: controversial Thymidylate synthase: Pemetrexed ERCC1 / RRM1: Cisplatin and Gemcitabine EML4-ALK translocation: Crizotinib,Alectinib,Ceritinib c-Met amplification: MetMAb ，ARQ-197 VEGF: Bevacizumab DD
